...
search icon
enlv-img

Enlivex Therapeutics Ltd Share Price

ENLV
NAQ
$1.05
-$0.07
(-6.25%)
1D
Industry: Software Sector: Information Technology

Enlivex Therapeutics Ltd Analyst Forecast

Enlivex Therapeutics Ltd Share Price Chart

Enlivex Therapeutics Ltd Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$265.87M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
150.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.59
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.66 L
$2.1 H
$1.05

About Enlivex Therapeutics Ltd, Common Stock

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel. more

Industry: SoftwareSector: Information Technology

Enlivex Therapeutics Ltd Stock Returns

Time FrameENLVSectorS&P500
1-Week Return-4.55%1.22%0.74%
1-Month Return7.14%-0.66%1.28%
3-Month Return11.82%0.3%3.6%
6-Month Return-7.72%7.31%
1-Year Return-16.37%11.97%
3-Year Return-72.73%106.46%72.07%
5-Year Return-94.14%107.14%76.01%
10-Year Return-99.13%593.11%258.47%

Enlivex Therapeutics Ltd Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue2.28M----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue286.00K546.00K777.00K835.00K545.00K[{"date":"2020-12-31","value":34.25,"profit":true},{"date":"2021-12-31","value":65.39,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":65.27,"profit":true}]
Gross Profit(286.00K)(546.00K)(777.00K)(835.00K)(545.00K)[{"date":"2020-12-31","value":-28600000,"profit":false},{"date":"2021-12-31","value":-54600000,"profit":false},{"date":"2022-12-31","value":-77700000,"profit":false},{"date":"2023-12-31","value":-83500000,"profit":false},{"date":"2024-12-31","value":-54500000,"profit":false}]
Gross Margin(12.56%)----[{"date":"2020-12-31","value":-12.56,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses9.79M19.29M25.80M29.39M14.99M[{"date":"2020-12-31","value":33.29,"profit":true},{"date":"2021-12-31","value":65.62,"profit":true},{"date":"2022-12-31","value":87.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":51,"profit":true}]
Operating Income(9.79M)(19.29M)(25.80M)(29.39M)(15.54M)[{"date":"2020-12-31","value":-978500000,"profit":false},{"date":"2021-12-31","value":-1928800000,"profit":false},{"date":"2022-12-31","value":-2579700000,"profit":false},{"date":"2023-12-31","value":-2939500000,"profit":false},{"date":"2024-12-31","value":-1553600000,"profit":false}]
Total Non-Operating Income/Expense(1.82M)4.61M(4.44M)1.88M1.58M[{"date":"2020-12-31","value":-39.46,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-96.31,"profit":false},{"date":"2023-12-31","value":40.72,"profit":true},{"date":"2024-12-31","value":34.22,"profit":true}]
Pre-Tax Income(11.82M)(14.47M)(31.06M)(29.07M)(15.01M)[{"date":"2020-12-31","value":-1182400000,"profit":false},{"date":"2021-12-31","value":-1446800000,"profit":false},{"date":"2022-12-31","value":-3106000000,"profit":false},{"date":"2023-12-31","value":-2906800000,"profit":false},{"date":"2024-12-31","value":-1501400000,"profit":false}]
Income Taxes2.04M(4.82M)11.35M4.24M-[{"date":"2020-12-31","value":17.97,"profit":true},{"date":"2021-12-31","value":-42.48,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.4,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(13.86M)(9.65M)(42.41M)(33.31M)-[{"date":"2020-12-31","value":-1386300000,"profit":false},{"date":"2021-12-31","value":-964800000,"profit":false},{"date":"2022-12-31","value":-4240700000,"profit":false},{"date":"2023-12-31","value":-3331200000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(11.82M)(14.47M)(31.06M)(27.16M)(15.01M)[{"date":"2020-12-31","value":-1182400000,"profit":false},{"date":"2021-12-31","value":-1446800000,"profit":false},{"date":"2022-12-31","value":-3106000000,"profit":false},{"date":"2023-12-31","value":-2716200000,"profit":false},{"date":"2024-12-31","value":-1501400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(11.82M)(14.47M)(31.06M)(29.07M)(15.01M)[{"date":"2020-12-31","value":-1182400000,"profit":false},{"date":"2021-12-31","value":-1446800000,"profit":false},{"date":"2022-12-31","value":-3106000000,"profit":false},{"date":"2023-12-31","value":-2906800000,"profit":false},{"date":"2024-12-31","value":-1501400000,"profit":false}]
EPS (Diluted)(0.71)-(2.24)(1.59)(0.77)[{"date":"2020-12-31","value":-71,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-224,"profit":false},{"date":"2023-12-31","value":-159,"profit":false},{"date":"2024-12-31","value":-77,"profit":false}]

Enlivex Therapeutics Ltd Ratios

Enlivex Therapeutics Ltd Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ENLV
Cash Ratio 6.04
Current Ratio 6.43

Enlivex Therapeutics Ltd Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ENLV
ROA (LTM) -36.02%
ROE (LTM) -57.64%

Enlivex Therapeutics Ltd Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ENLV
Debt Ratio Lower is generally better. Negative is bad. 0.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.83

Enlivex Therapeutics Ltd Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ENLV
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 14.94
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Enlivex Therapeutics Ltd share price today?

Enlivex Therapeutics Ltd (ENLV) share price today is $1.05

Can Indians buy Enlivex Therapeutics Ltd shares?

Yes, Indians can buy shares of Enlivex Therapeutics Ltd (ENLV) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENLV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Enlivex Therapeutics Ltd be purchased?

Yes, you can purchase fractional shares of Enlivex Therapeutics Ltd (ENLV) via the Vested app. You can start investing in Enlivex Therapeutics Ltd (ENLV) with a minimum investment of $1.

How to invest in Enlivex Therapeutics Ltd shares from India?

You can invest in shares of Enlivex Therapeutics Ltd (ENLV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ENLV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Enlivex Therapeutics Ltd shares
What is Enlivex Therapeutics Ltd 52-week high and low stock price?

The 52-week high price of Enlivex Therapeutics Ltd (ENLV) is $2.1. The 52-week low price of Enlivex Therapeutics Ltd (ENLV) is $0.66.

What is Enlivex Therapeutics Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Enlivex Therapeutics Ltd (ENLV) is

What is Enlivex Therapeutics Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Enlivex Therapeutics Ltd (ENLV) is 14.94

What is Enlivex Therapeutics Ltd dividend yield?

The dividend yield of Enlivex Therapeutics Ltd (ENLV) is 0.00%

What is the Market Cap of Enlivex Therapeutics Ltd?

The market capitalization of Enlivex Therapeutics Ltd (ENLV) is $265.87M

What is Enlivex Therapeutics Ltd's stock symbol?

The stock symbol (or ticker) of Enlivex Therapeutics Ltd is ENLV

How Can Investors Use Enlivex Therapeutics Ltd Share Price Data for Long-Term Investment Decisions?

Consider the share price of Enlivex Therapeutics Ltd as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Enlivex Therapeutics Ltd has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Enlivex Therapeutics Ltd shares for Indian investors?

When investing in Enlivex Therapeutics Ltd shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Enlivex Therapeutics Ltd stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Enlivex Therapeutics Ltd share price with other stocks in the same sector?

Rather than merely checking the share price of Enlivex Therapeutics Ltd and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Enlivex Therapeutics Ltd stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top